Surmodics Inc
NASDAQ:SRDX

Watchlist Manager
Surmodics Inc Logo
Surmodics Inc
NASDAQ:SRDX
Watchlist
Price: 39.33 USD 0.36% Market Closed
Market Cap: 561.1m USD
Have any thoughts about
Surmodics Inc?
Write Note

Surmodics Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Surmodics Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Surmodics Inc
NASDAQ:SRDX
Accounts Receivables
$23.2m
CAGR 3-Years
12%
CAGR 5-Years
6%
CAGR 10-Years
17%
Becton Dickinson and Co
NYSE:BDX
Accounts Receivables
$3B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
10%
Boston Scientific Corp
NYSE:BSX
Accounts Receivables
$2.5B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
7%
Stryker Corp
NYSE:SYK
Accounts Receivables
$3.7B
CAGR 3-Years
10%
CAGR 5-Years
9%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Accounts Receivables
$6.9B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Accounts Receivables
$1.2B
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
16%
No Stocks Found

Surmodics Inc
Glance View

Market Cap
561.1m USD
Industry
Health Care

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

SRDX Intrinsic Value
15.29 USD
Overvaluation 61%
Intrinsic Value
Price

See Also

What is Surmodics Inc's Accounts Receivables?
Accounts Receivables
23.2m USD

Based on the financial report for Sep 30, 2024, Surmodics Inc's Accounts Receivables amounts to 23.2m USD.

What is Surmodics Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
17%

Over the last year, the Accounts Receivables growth was 24%. The average annual Accounts Receivables growth rates for Surmodics Inc have been 12% over the past three years , 6% over the past five years , and 17% over the past ten years .

Back to Top